Patents by Inventor DaWei Cui

DaWei Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20240059733
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: February 17, 2023
    Publication date: February 22, 2024
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Pyruvate kinase modulators and use thereof
    Patent number: 11872225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3- DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    Publication number: 20240002362
    Abstract: The present invention relates to a deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide inhibitor, a preparation method therefor, and an application thereof. Specifically, the compound of the present invention has the structure shown in formula (I); also disclosed in the present invention are a preparation method for said compound and the use thereof as an AhR inhibitor; the compound of the present invention has a good selective inhibitory effect on AhR, and has better pharmacodynamics, pharmacokinetic properties, and lower toxic and side effects.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 4, 2024
    Inventors: Binhua LV, Dawei CUI, Lianjun LIU, Xudong PANG, Chuanke CHAI
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20230226055
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Therapeutically active compounds and their methods of use
    Patent number: 11667673
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 6, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
    Publication number: 20230118795
    Abstract: The present invention relates to an aryl or heteroaryl pyridone or pyrimidine derivative, and a preparation method and use thereof. Specifically, the compounds of the present invention have a structure represented by formula (I). Further disclosed in the present invention are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic, pharmacokinetic performance, and reduced toxic side effects.
    Type: Application
    Filed: January 12, 2021
    Publication date: April 20, 2023
    Inventors: Binhua LV, Dawei CUI, Lianjun LIU
  • CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF
    Publication number: 20230105745
    Abstract: Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.
    Type: Application
    Filed: June 2, 2022
    Publication date: April 6, 2023
    Inventors: Binhua LV, Dawei CUI, Lianjun LIU, Tao HAN, Runqing WANG, Peizhong NI, Zelin SHENG
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11590132
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 28, 2023
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF
    Publication number: 20230008368
    Abstract: The present invention relates to an imidazoquinoline substituted phosphoric ester agonist, and a preparation therefor and an application thereof. Specifically, the compounds of the present invention have the structure shown in formula (I), wherein the definition of each group and substituent is as described in the description. Also disclosed in the present invention are a preparation method for the compound and use thereof as a TLR agonist.
    Type: Application
    Filed: November 11, 2020
    Publication date: January 12, 2023
    Inventors: Binhua LV, Dawei CUI, Chuanke CHAI, Ruifeng LIU, Zelin SHENG
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20220395503
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 15, 2022
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase modulators and use thereof
    Patent number: 11464775
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 11, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof
    Patent number: 11459327
    Abstract: Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: October 4, 2022
    Assignees: Suzhou Zelgen Biopharmaceuticals Co., Ltd., Shanghai Zelgen Pharma.Tech Co., Ltd.
    Inventors: Binhua Lv, Dawei Cui, Lianjun Liu, Tao Han, Runqing Wang, Peizhong Ni, Zelin Sheng
  • PYRUVATE KINASE MODULATORS AND USE THEREOF
    Publication number: 20220233541
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11364240
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Pyruvate kinase activators for use in treating blood disorders
    Patent number: 11040036
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: June 22, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Therapeutically active compounds and their methods of use
    Patent number: 11021515
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: June 1, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210130371
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210077490
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20210024575
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: June 5, 2020
    Publication date: January 28, 2021
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20200339626
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: May 11, 2020
    Publication date: October 29, 2020
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou